We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Geistlich Pharma North America, Inc. Announces Acquisition of Lynch Biologics, LLC

OCTOBER 26, 2022 — Geistlich Pharma North America is proud to announce the acquisition of Lynch Biologics, LLC, the developer, and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential.

The combination of two regenerative leaders offers:

  • Expanded regenerative solutions for clinicians and their patients
  • A combined team of purpose-driven leaders and highly skilled experts
  • Strengthened product development, clinical research, and education on new regenerative technologies
  • A shared commitment to research, quality, and safety

Listen below as Les Burrows, General Manager of Geistlich Pharma North America, and Sam Lynch, DMD, DMSC, CEO of Lynch Biologics, discuss the details of the acquisition, the benefits to our customers, and the opportunities this brings to support our mission to drive regeneration.


To learn more, please contact our Customer Care toll-free at 855-799-5500 or email us directly at infogeistlich-na.com.

View Press Release Here